CM
MCID: MLR004
MIFTS: 77

Malaria (CM)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Infectious diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Malaria

MalaCards integrated aliases for Malaria:

Name: Malaria 57 11 19 58 75 53 41 2 43 14 16 71 33
Malaria, Susceptibility to 57 28 5 38
Malaria, Resistance to 57 12 5
Malaria, Cerebral 57 43 71
Cerebral Malaria 11 14 16
Malaria, Cerebral, Susceptibility to 57 5
Malaria, Severe, Susceptibility to 57 5
Malaria, Severe, Resistance to 57 5
Induced Malaria 11 71
Clinically Diagnosed Malaria Without Parasitological Confirmation 33
Resistance to Malaria Due to G6pd Deficiency 57
Falciparum Malaria [malignant Tertian] 33
Subtertian Malignant Tertian Malaria 33
Severe Plasmodium Falciparum Malaria 33
Malaria, Vivax, Protection Against 57
Malaria, Cerebral, Reduced Risk of 57
Mtm - [malignant Tertian Malaria] 33
Malaria Fever by Plasmodium Ovale 33
Tm -[malignant Tertian Malaria] 33
Plasmodium Malariae Malaria Nos 33
Malaria Due to G6pd Deficiency 57
Malaria by Plasmodium Malariae 33
Estivo-Autumnal Malarial Fever 33
Btm - [benign Tertian Malaria] 33
Pernicious Intermittent Fever 33
Bilious Haemoglobinuric Fever 33
Bt - [benign Tertian Malaria] 33
Plasmodium Vivax Malaria Nos 33
Benign Tertian Vivax Malaria 33
Clinically Diagnosed Malaria 33
Malaria, Protection Against 57
Malaria by Plasmodium Ovale 33
Disease Due to Plasmodiidae 33
Severe Malarial Falciparum 33
Remittent Congestive Fever 33
Congestive Remittent Fever 33
Intermittent Bilious Fever 33
Susceptibility to Malaria 16
Malignant Tertian Malaria 33
Malarial Blackwater Fever 33
St - [subtertian Malaria] 33
Aestivo Autumnal Malaria 33
Subtertian Malaria Fever 33
Malarial Haemoglobinuria 33
Malignant Tertian Fever 33
Continued Malaria Fever 33
Estivo-Autumnal Malaria 33
Haemoglobinuric Malaria 33
Remittent Gastric Fever 33
Acute Pernicious Fever 33
Aestivo-Autumnal Fever 33
Benign Tertian Malaria 33
Plasmodium Ovale Fever 33
Malarial Encephalitis 11
Estivo-Autumnal Fever 33
Malarial Haematinuria 33
Haemoglobinuric Fever 33
Chagres Virus Disease 33
Ovale Tertian Malaria 33
Malarial Haematuria 33
Pernicious Malaria 33
West African Fever 33
Malarial Quotidian 33
Intermittent Fever 33
Black Water Fever 33
Quotidian Malaria 33
Malignant Malaria 33
Malaria Fever Nos 33
Malarial Cachexia 33
Recurrent Malaria 33
Remittent Malaria 33
Blackwater Fever 33
Malaria Cerebral 53
Falciparum Fever 33
Subtertian Fever 33
Tropical Malaria 33
Quartan Malarial 33
Malariae Malaria 33
Congestive Fever 33
Paludal Cachexia 33
Malaria, Severe 57
Quartan Malaria 33
Malaria Tropica 33
Tertian Malaria 33
Miasmatic Fever 33
Remittent Fever 33
Malarial Shock 33
Malarial Ovale 33
Cameroon Fever 33
Corsican Fever 33
Malarial Fever 33
Marsh Cachexia 33
Ovale Malaria 33
Vivax Malaria 33
Chagres Fever 33
Algid Malaria 33
Quartan Fever 33
Coastal Fever 33
Paludal Fever 33
Panama Fever 33
Tertian Ague 33
Quartan Ague 33
Jungle Fever 33
Plasmodiosis 33
Vivax Fever 33
Marsh Fever 33
Roman Fever 33
Malaria Nos 33
Paludism 33
Ague 33
Cm 47

Characteristics:


Prevelance:

1-9/100000 (Europe, Europe, Denmark, Belgium, Ireland, Malta, Netherlands, Portugal, Spain, Sweden, United Kingdom, Norway) 1-9/1000000 (Iceland, Austria, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Finland, Greece, Hungary, Latvia, Lithuania, Luxembourg, Romania, Slovenia) <1/1000000 (Poland, Slovakia) 58

Age Of Onset:

All ages 58

Age Of Death:

any age 58

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Malaria

OMIM®: 57 Malaria, a major cause of child mortality worldwide, is caused by mosquito-borne hematoprotozoan parasites of the genus Plasmodium. Of the 4 species that infect humans, P. falciparum causes the most severe forms of malaria and is the major cause of death and disease. Although less fatal, P. malariae, P. ovale, and, in particular, P. vivax infections are major causes of morbidity. The parasite cycle involves a first stage in liver cells and a subsequent stage at erythrocytes, when malaria symptoms occur. A wide spectrum of phenotypes are observed, from asymptomatic infection to mild disease, including fever and mild anemia, to severe disease, including cerebral malaria, profound anemia, and respiratory distress. Genetic factors influence the response to infection, as well as disease progression and severity. Malaria is the strongest known selective pressure in the recent history of the human genome, and it is the evolutionary driving force behind sickle-cell disease (603903), thalassemia (see 141800), glucose-6-phosphatase deficiency (300908), and other erythrocyte defects that together constitute the most common mendelian diseases of humans (Kwiatkowski, 2005; Campino et al., 2006). (611162) (Updated 24-Oct-2022)

MalaCards based summary: Malaria, also known as malaria, susceptibility to, is related to plasmodium falciparum malaria and plasmodium vivax malaria, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Malaria is SLC4A1 (Solute Carrier Family 4 Member 1 (Diego Blood Group)), and among its related pathways/superpathways are Innate Immune System and Response to elevated platelet cytosolic Ca2+. The drugs Lumefantrine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include spleen, liver and t cells, and related phenotypes are nausea and vomiting and fever

MedlinePlus: 41 Malaria is a serious disease caused by a parasite. You get it when an infected mosquito bites you. Malaria is a major cause of death worldwide, but it is almost wiped out in the United States. The disease is mostly a problem in developing countries with warm climates. If you travel to these countries, you are at risk. There are four different types of malaria caused by four related parasites. The most deadly type occurs in Africa south of the Sahara Desert. Malaria symptoms include chills, flu-like symptoms, fever, vomiting, diarrhea, and jaundice. A blood test can diagnose it. It can be life-threatening. However, you can treat malaria with drugs. The type of drug depends on which kind of malaria you have and where you were infected. Malaria can be prevented. When traveling to areas where malaria is found: See your doctor for medicines that protect you Wear insect repellent with DEET Cover up Sleep under mosquito netting Centers for Disease Control and Prevention

Disease Ontology 11 Malaria: A parasitic protozoa infectious disease characterized as a vector-borne infectious disease caused by the presence of protozoan parasites of the genus Plasmodium in the red blood cells, transmitted from an infected to an uninfected individual by the bite of anopheline mosquitoes, and characterized by periodic attacks of chills and fever that coincide with mass destruction of blood cells and the release of toxic substances by the parasite at the end of each reproductive cycle.

Cerebral malaria: A malaria that involves neurologic damage resulting from blockage of the blood vessels, caused due to the infection of the red blood cells by Plasmodium species.

GARD: 19 Malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. Infection with Malaria parasites may result in a wide variety of symptoms, ranging from absent or very mild symptoms to severe disease and even death. People who get Malaria are typically very sick with high fevers, shaking chills, and flu-like illness.

CDC: 2 Malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. People who get malaria are typically very sick with high fevers, shaking chills, and flu-like illness. Although malaria can be a deadly disease, illness and death from malaria can usually be prevented.

Orphanet: 58 A life-threatening parasitic disease caused by Plasmodium (P. ) parasites that are transmitted by Anophles mosquito bites to humans and is typically clinically characterized by attacks of fever, headache, chills and vomiting.

Wikipedia: 75 Malaria is a mosquito-borne infectious disease that affects humans and other animals. Malaria causes... more...

Related Diseases for Malaria

Diseases related to Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1227)
# Related Disease Score Top Affiliating Genes
1 plasmodium falciparum malaria 34.3 TNF SLC4A1 NOS2 ICAM1 HBB G6PD
2 plasmodium vivax malaria 33.8 TNF GYPC GYPA G6PD ACKR1
3 glucosephosphate dehydrogenase deficiency 33.0 TNF SLC4A1 HBB GYPA G6PD ACKR1
4 deficiency anemia 32.7 TNF SLC4A1 LOC107133510 LOC106099062 HBB GYPA
5 dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edema 32.4 SLC4A1 HBB GYPC GYPA
6 adult respiratory distress syndrome 32.3 TNF NOS2 FCGR2A CR1
7 sickle cell anemia 32.0 TNF LOC110006319 LOC107133510 LOC106099062 ICAM1 HBB
8 hereditary elliptocytosis 31.9 SLC4A1 HBB GYPC GYPB GYPA G6PD
9 pulmonary edema 31.8 TNF NOS2 ICAM1
10 autoimmune disease 31.7 TNF NOS2 ICAM1 FCGR2B FCGR2A
11 hemolytic anemia 31.6 SLC4A1 LOC107133510 LOC106099062 HBB GYPA G6PD
12 proteasome-associated autoinflammatory syndrome 1 31.6 TNF NOS2 ICAM1
13 thalassemia 31.6 SLC4A1 LOC110006319 LOC107133510 HBB G6PD
14 respiratory failure 31.6 TNF SLC4A1 ICAM1 G6PD
15 glomerulonephritis 31.6 TNF NOS2 ICAM1 CR1
16 acquired immunodeficiency syndrome 31.6 TNF NOS2 ICAM1
17 hepatitis a 31.4 TNF GYPA G6PD
18 poliomyelitis 31.4 TNF ICAM1 FCGR2A
19 alpha-thalassemia 31.4 TNF SLC4A1 LOC110006319 LOC107133510 LOC106099062 HBB
20 sickle cell disease 31.3 LOC110006319 LOC107133510 LOC106099062 HBB G6PD
21 meningitis 31.2 TNF ICAM1 FCGR2A
22 hereditary spherocytosis 31.2 SLC4A1 HBB GYPC GYPB GYPA G6PD
23 hemoglobinopathy 31.1 LOC110006319 LOC107133510 LOC106099062 HBB GYPA G6PD
24 hemoglobin c disease 31.0 LOC107133510 LOC106099062 HBB
25 hemoglobin se disease 30.9 LOC110006319 LOC107133510 LOC106099062 HBB
26 hemoglobin e disease 30.9 LOC107133510 LOC106099062 HBB
27 beta-thalassemia 30.9 SLC4A1 LOC110006319 LOC107133510 LOC106099062 HBB G6PD
28 peritonitis 30.7 TNF ICAM1 CR1
29 priapism 30.7 SLC4A1 NOS2 HBB
30 hypersensitivity reaction type iii disease 30.7 TNF FCGR2B FCGR2A CR1
31 rheumatoid arthritis 30.6 TNF NOS2 ICAM1 FCGR2B FCGR2A CR1
32 congenital hemolytic anemia 30.4 SLC4A1 HBB GYPA G6PD
33 myasthenia gravis 30.4 TNF FCGR2A CR1
34 interstitial lung disease 2 30.3 TNF ICAM1 CR1 CD36
35 fetal hemoglobin quantitative trait locus 1 30.3 LOC110006319 LOC107133510 LOC106099062 HBB
36 hemoglobin e-beta-thalassemia syndrome 30.3 LOC107133510 LOC106099062 HBB
37 herpes simplex virus keratitis 30.2 GYPC ACKR1
38 carrion's disease 30.2 GYPB GYPA
39 acute necrotizing pancreatitis 30.2 TNF ICAM1
40 labyrinthitis 30.2 TNF GYPC
41 acute hemorrhagic encephalitis 30.0 ICAM1 CD36
42 beta-thalassemia major 29.8 LOC110006319 LOC107133510 LOC106099062 HBB GYPA
43 methemoglobinemia, beta-globin type 29.7 LOC110006319 LOC107133510 LOC106099062 HBB
44 heinz body anemias 29.7 LOC110006319 LOC107133510 LOC106099062 HBB
45 plasmodium malariae malaria 11.6
46 plasmodium ovale malaria 11.5
47 mixed malaria 11.5
48 blackwater fever 11.4
49 malaria, mild 11.3
50 disease by infectious agent 11.2

Graphical network of the top 20 diseases related to Malaria:



Diseases related to Malaria

Symptoms & Phenotypes for Malaria

Human phenotypes related to Malaria:

58 30 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002017
2 fever 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001945
3 anemia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001903
4 headache 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002315
5 acute kidney injury 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001919
6 elevated circulating c-reactive protein concentration 30 Hallmark (90%) HP:0011227
7 morphological central nervous system abnormality 30 Hallmark (90%) HP:0002011
8 reduced consciousness/confusion 58 30 Frequent (33%) Frequent (79-30%)
HP:0004372
9 cognitive impairment 58 30 Frequent (33%) Frequent (79-30%)
HP:0100543
10 thrombocytopenia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001873
11 myalgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0003326
12 gait imbalance 58 30 Frequent (33%) Frequent (79-30%)
HP:0002141
13 hyperbilirubinemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002904
14 respiratory distress 58 30 Frequent (33%) Frequent (79-30%)
HP:0002098
15 retinopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000488
16 morphological abnormality of the central nervous system 58 Very frequent (99-80%)
17 elevated c-reactive protein level 58 Very frequent (99-80%)
18 abnormality of blood and blood-forming tissues 58 Frequent (79-30%)

Clinical features from OMIM®:

611162 (Updated 24-Oct-2022)

UMLS symptoms related to Malaria:


angina pectoris; chest pain; edema; fever; pruritus; remittent fever

MGI Mouse Phenotypes related to Malaria:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 ACKR1 CD36 CISH CR1 FCGR2A FCGR2B
2 immune system MP:0005387 9.77 ACKR1 CD36 CISH CR1 FCGR2A FCGR2B
3 hematopoietic system MP:0005397 9.5 CD36 CISH CR1 FCGR2A FCGR2B G6PD

Drugs & Therapeutics for Malaria

Drugs for Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 273)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lumefantrine Approved Phase 4 82186-77-4 6437380
2
Artemether Approved Phase 4 71963-77-4 68911 9796294
3
Quinidine Approved, Investigational Phase 4 56-54-2, 130-95-0, 804-63-7 1065 441074 3034034 8549
4
Azithromycin Approved Phase 4 83905-01-5 447043
5
Iron Approved Phase 4 7439-89-6 29936
6
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
7
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
8
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
9
Copper Approved, Investigational Phase 4 7440-50-8 27099
10
Mecobalamin Approved, Investigational Phase 4 13422-55-4
11
Iodine Approved, Investigational Phase 4 7553-56-2 807
12
Tocopherol Approved, Investigational Phase 4 1406-66-2
13
Selenium Approved, Investigational, Vet_approved Phase 4 7783-07-5, 7782-49-2 533
14
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
15
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
16
Sulfamethoxazole Approved Phase 4 723-46-6 5329
17
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
18
Morphine Approved, Investigational Phase 4 57-27-2 5288826
19
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
20
Lopinavir Approved Phase 4 192725-17-0 92727
21
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
22
Promethazine Approved, Investigational Phase 4 60-87-7 4927
23
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
24
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
25
Ferrous fumarate Approved Phase 4 141-01-5
26
Ibuprofen Approved Phase 4 15687-27-1 3672
27
Piperaquine Approved, Experimental, Investigational Phase 4 4085-31-8
28
Artenimol Approved, Experimental, Investigational Phase 4 71939-50-9 540327
29
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
30
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
31
Dolutegravir Approved Phase 4 1051375-16-6 57414794 54726191
32
Lactitol Approved, Investigational Phase 4 585-86-4, 585-88-6 157355 493591
33
Nevirapine Approved Phase 4 129618-40-2 4463
34
BCG vaccine Approved, Investigational Phase 4
35
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
36
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 24892734 16212801 44176380
37
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
38
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
39
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
40
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
41
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
42
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
43
Cadexomer iodine Experimental Phase 4 94820-09-4
44
Tocotrienol Investigational Phase 4 6829-55-6 9929901
45
Cobalamin Experimental Phase 4 13408-78-1 6857388
46
Methaqualone Illicit, Withdrawn Phase 4 72-44-6 6292
47
Pyronaridine Investigational Phase 4 74847-35-1 5485198
48 Artemether, Lumefantrine Drug Combination Phase 4
49 Analgesics, Non-Narcotic Phase 4
50 Analgesics Phase 4

Interventional clinical trials:

(show top 50) (show all 1246)
# Name Status NCT ID Phase Drugs
1 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Impact of Insecticide Resistance in Anopheles Arabiensis on the Effectiveness of Malaria Vector Control in Sudan Unknown status NCT01713517 Phase 4
3 Programmatic Implementation of ACTs in Malawi: Safety and Effectiveness of Combination Therapies With Repeated Treatments for Uncomplicated P. Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
4 Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
5 An Open Label Randomized Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4 Artesunate;Chloroquine
6 Cluster Randomised Trial to Compare Effectiveness of the Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) to LLINs Alone for Malaria Prevention in Muleba District, Kagera Region, Tanzania Unknown status NCT01697852 Phase 4
7 Efficacy of Artesunate Monotherapy and Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Central Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
8 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4 Dihydroartemisinin- piperaquine;artemether- lumefantrine
9 The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau Unknown status NCT00137566 Phase 4 acetaminophen (paracetamol)
10 A Randomized, Double Blind Trial on the Efficacy and Safety of Amodiaquine-Artesunate and Amodiaquine Alone in the Treatment of Children With Uncomplicated Falciparum Malaria Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
11 Intermittent Treatment With Sulfadoxine-Pyrimethamine for Malaria Control in Children: A Randomised, Double Blind, and Placebo-Controlled Clinical Trial Unknown status NCT00168948 Phase 4 Sulfadoxin (12.5) Pyrimethamine (250 mg)
12 Single Low-dose Primaquine Efficacy and Safety for Treatment of Uncomplicated Plasmodium Falciparum Malaria Based on Cytochrome P450 2D6 Activity in Bagamoyo District, Tanzania. Unknown status NCT03352843 Phase 4 Primaquine
13 Confirmation of Artemisinin Tolerance in Malaria Parasites Trial in Kilifi Unknown status NCT01190371 Phase 4 Artesunate
14 Intravenous Artesunate Versus Quinine in Severe Malaria at Kassla, Sudan Unknown status NCT01805232 Phase 4 artesunate;Quinine
15 Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children Unknown status NCT00540202 Phase 4 artemether-lumefantrine;Oral quinine
16 THE OPTIMAL TIMING OF PRIMAQUINE TO PREVENT MALARIA TRANSMISSION AFTER ARTEMISININ-COMBINATION THERAPY Unknown status NCT01906788 Phase 4 Artemether Lumefantrine;Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0;Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2
17 Evaluation of the Public Health Impact and Cost Effectiveness of Seasonal Intermittent Preventive Treatment in Children in Senegal Unknown status NCT00712374 Phase 4 sulfadoxine-pyrimethamine plus amodiaquine
18 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics of Lumefantrine and Population Pharmacokinetics of Lumefantrine Among Ugandan Children Unknown status NCT01944189 Phase 4
19 A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant Papua New Guinean Women Unknown status NCT02575755 Phase 4 Azithromycin plus piperaquine phosphate;Sulfadoxine-pyrimethamine
20 Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam Unknown status NCT02610686 Phase 4 Chloroquine
21 Safety, Tolerability and Pilot Efficacy of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection Unknown status NCT02364583 Phase 4 Primaquine
22 Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas - a Randomized Controlled Trial Completed NCT03916003 Phase 4 primaquine
23 An Individually Randomised Trial of Seasonal Malaria Chemoprevention Versus a Long-acting Artemisinin Combination Therapy for the Prevention of Malaria and Anaemia in Children Living in an Area of Extended Seasonal Transmission in Ghana. Completed NCT01651416 Phase 4 Artemether-lumefantrine combination;Dihydroartemisinin Piperaquine combination;Amodiaquine plus sulphadoxine-pyrimethamine combination
24 Chloroquine and Sulfadoxine-Pyrimethamine Efficacy for the Treatment of Uncomplicated Falciparum Malaria in Blantyre, Malawi Completed NCT00125489 Phase 4 chloroquine sulfate;sulfadoxine/pyrimethamine
25 Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso: the Malaria Component Completed NCT00680732 Phase 4 Chloroquine (CQ);Sulphadoxyne-pyrimethamine (SP)
26 Extended Duration Artemether-lumefantrine Treatment for Malaria in Children Completed NCT03453840 Phase 4 Artemether-lumefantrine
27 G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria Completed NCT02876549 Phase 4 Chloroquine;Primaquine 0.25 mg/kg/day;Primaquine 0.75 mg/kg weekly
28 Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, the Standard Treatment Recommended by the Ministry of the Social Protection in Colombia for the Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia) Completed NCT04877626 Phase 4 Artemeter plus lumefantrina vs artesunato plus amodiquina
29 Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Five Years After Wide Scale Use of the Drug in Tanzania. Completed NCT02089841 Phase 4 Artemether-lumefantrine
30 Assessing Chloroquine Resistance of Plasmodium Vivax in Malaria Endemic Area Completed NCT02118090 Phase 4 Chloroquine sulfate;DHA-PP
31 Efficacy of Antimalarial Drugs Used for the Treatment of Uncomplicated Malaria, Plasmodium Falciparum, at the Agadez, Gaya and Tessaoua Sentinel Sites Completed NCT05070520 Phase 4 Artemether-lumefantrine
32 An Open Randomised Trial of the Efficacy of Sulfadoxine-Pyrimethamine (SP), Amodiaquine + SP (AQ-SP), AQ + Artesunate (AQ-Art), Chlorproguanil-Dapsone + Art (CD-Art), and Lumefantrine-Artemether (LA) for Uncomplicated Malaria in Malawi Completed NCT00164710 Phase 4 sulfadoxine-pyrimethamine;amodiaquine plus sulfadoxine-pyrimethamine;amodiaquine plus artesunate;chlorproguanil-dapsone plus artesunate;lumefantrine-artemether
33 The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children With Recrudescent Malaria in Guinea-Bissau Completed NCT00137553 Phase 4 Sulfadoxine-pyrimethamine (Fansidar)
34 Chloroquine and Amodiaquine for Treatment of Symptomatic Children With Plasmodium Malaria in Guinea-Bissau Completed NCT00137514 Phase 4 chloroquine;amodiaquine
35 Artemether-lumefantrine Vs Co-formulated Amodiaquine + Artesunate for the Treatment of Uncomplicated Falciparum Malaria: a Randomized Open-label Trial to Evaluate the Effectiveness of the Burkina Faso New Drug Policy Completed NCT01017770 Phase 4 Artesunate-amodiaquine;Artemether-lumefantrine
36 A Multicentre Randomised Comparative Clinical Trial of the Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine (Coartem®) for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Zanzibar Completed NCT03768908 Phase 4 Artemether-lumefantrine;Artesunate + Amodiaquine
37 Randomized Study of the Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate Plus Amodiaquine Coadministered for the Treatment of Uncomplicated Falciparum Malaria in Zanzibar Completed NCT03764527 Phase 4 Artemether-lumefantrine;Coadministered Artesunate plus Amodiaquine
38 A Randomized Study to Compare Artesunate + Amiodaquine Versus Artemether + Lumefantrine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During 2 Years in a Cohort in Senegal Completed NCT00540410 Phase 4 Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination);Coartem® (arthemether+ lumefantrine)
39 A Randomized Open-Label Trial of the Efficacy of Artemether-Lumefantrine Suspension Compared With Artemether-Lumefantrine Tablets for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Less Than Five Years in Western Kenya Completed NCT00529867 Phase 4 Artemether/lumefantrine tablets;Artemether/Lumefantrine suspension
40 Open-label, Multi-center, Non-comparative Efficacy, Safety, and Tolerability Study of Co-artemether in the Treatment of Acute Uncomplicated Malaria in Non-immune Patients Completed NCT00233337 Phase 4 Co-artemether
41 Efficacy and Safety of Artesunate + Amodiaquine Combined With a Single Low Dose of Primaquine (0.25 mg/kg) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Zanzibar Completed NCT03773536 Phase 4 Artesunate-amodiaquine given with single low dose primaquine
42 A Randomised Study to Compare a Fixed Dose Combination of Artesunate Plus Amiodaquine (Coarsucam) Versus a Fixed Dose Combination of Artemether Plus Lumefantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During the 2 Years of Follow-up, in Children in Uganda. Completed NCT00699920 Phase 4 Coarsucam;Coartem
43 Efficacy of Amodiaquine-artesunate in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children at an IPTi Site in Rural Western Kenya Completed NCT00425763 Phase 4 AQAS
44 Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers Completed NCT00301015 Phase 4
45 A Double-blind Randomised Trial to Assess the Tolerability of Amodiaquine Plus Artesunate (AQ-Art) Versus Chlorproguanil Plus Dapsone Plus Artesunate (CDA) in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi Completed NCT00164359 Phase 4 Amodiaquine plus artesunate;chlorproguanil-dapsone plus artesunate
46 Clinical Trial of Extended-dose Chloroquine Versus Standard Chloroquine Treatment for Resistant Falciparum Malaria Among Afghan Refugees in NWFP Pakistan Completed NCT01019408 Phase 4 Chloroquine
47 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Completed NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
48 Efficacy and Safety of Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania Completed NCT03431714 Phase 4 Artesunate amodiaquine
49 In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated Plasmodium Falciparum Malaria in Malawi, 2014 Completed NCT02637128 Phase 4 artemether-lumefantrine (AL);artesunate-amodiaquine (ASAQ)
50 A Multicentre, Randomised Trial to Detect in Vivo Resistance of Plasmodium Falciparum to Artesunate in Patients With Uncomplicated Malaria. Completed NCT01350856 Phase 4 Artesunate 2;Artesunate 4

Search NIH Clinical Center for Malaria

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Antimalarial [EPC]
artemether
Atovaquone
Chloroquine
Chloroquine hydrochloride
chloroquine phosphate
Dihydrofolate Reductase Inhibitor Antimalarial [EPC]
halofantrine
Halofantrine hydrochloride
Hydroxychloroquine
Hydroxychloroquine Sulfate
lumefantrine
Mefloquine
Mefloquine Hydrochloride
Pentoxifylline
Primaquine
Primaquine Phosphate
Proguanil
Pyrimethamine
Quinine
QUININE SO4 PWDR
Quinine Sulfate

Cochrane evidence based reviews: malaria

Genetic Tests for Malaria

Genetic tests related to Malaria:

# Genetic test Affiliating Genes
1 Malaria, Susceptibility to 28 ACKR1 CD36 CISH CR1 FCGR2A FCGR2B G6PD GYPA GYPB GYPC HBB ICAM1 NOS2 SLC4A1 TIRAP TNF

Anatomical Context for Malaria

Organs/tissues related to Malaria:

MalaCards : Spleen, Liver, T Cells, Whole Blood, Kidney, Brain, B Cells

Publications for Malaria

Articles related to Malaria:

(show top 50) (show all 36220)
# Title Authors PMID Year
1
How malaria has affected the human genome and what human genetics can teach us about malaria. 53 62 57 5
16001361 2005
2
A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. 53 62 57 5
14694201 2004
3
A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. 53 62 57 5
12433515 2002
4
A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. 53 62 57 5
10369255 1999
5
Absence of an association between intercellular adhesion molecule 1, complement receptor 1 and interleukin 1 receptor antagonist gene polymorphisms and severe malaria in a West African population. 53 62 57 5
9861406 1998
6
A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya. 53 62 57 5
9259284 1997
7
Sickle hemoglobin confers tolerance to Plasmodium infection. 62 57 5
21529713 2011
8
FCGR2A functional genetic variant associated with susceptibility to severe malarial anaemia in Ghanaian children. 62 57 5
19965803 2010
9
A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus. 62 57 5
20385827 2010
10
A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. 62 57 5
17322885 2007
11
Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria. 62 57 5
17435165 2007
12
Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. 62 57 5
15973412 2005
13
Hemoglobin C is associated with reduced Plasmodium falciparum parasitemia and low risk of mild malaria attack. 62 57 5
14613965 2004
14
The association of the glycophorin C exon 3 deletion with ovalocytosis and malaria susceptibility in the Wosera, Papua New Guinea. 62 57 5
11719395 2001
15
Malaria susceptibility and CD36 mutation. 62 57 5
10890433 2000
16
Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. 62 57 5
9457101 1998
17
Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand. 57 5
20855594 2010
18
Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations. 57 5
12469115 2003
19
A 3.5 kb deletion in the glycophorin C gene accounts for the Gerbich-negative blood group in Melanesians. 57 5
8157284 1994
20
The Gerbich blood group system, especially in Melanesians. 57 5
5011657 1972
21
A functional promoter variant in IL12B predisposes to cerebral malaria. 53 62 57
18413324 2008
22
Significant association between TIM1 promoter polymorphisms and protection against cerebral malaria in Thailand. 53 62 57
18294362 2008
23
Genome-wide linkage analysis of malaria infection intensity and mild disease. 53 62 57
17381244 2007
24
The beta -globin recombinational hotspot reduces the effects of strong selection around HbC, a recently arisen mutation providing resistance to malaria. 53 62 5
16175509 2005
25
CD36 polymorphism is associated with protection from cerebral malaria. 53 62 57
12506336 2003
26
Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. 53 62 57
9746794 1998
27
Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. 53 62 57
7617034 1995
28
Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. 53 62 57
7935762 1994
29
Common west African HLA antigens are associated with protection from severe malaria. 53 62 57
1865923 1991
30
Structural basis for RIFIN-mediated activation of LILRB1 in malaria. 62 57
32650338 2020
31
Common PIEZO1 Allele in African Populations Causes RBC Dehydration and Attenuates Plasmodium Infection. 62 57
29576450 2018
32
Erythrocytic ferroportin reduces intracellular iron accumulation, hemolysis, and malaria risk. 62 57
29599243 2018
33
Malaria parasites target the hepatocyte receptor EphA2 for successful host infection. 62 57
26612952 2015
34
A novel locus of resistance to severe malaria in a region of ancient balancing selection. 62 57
26416757 2015
35
Malaria. A forward genetic screen identifies erythrocyte CD55 as essential for Plasmodium falciparum invasion. 62 57
25954012 2015
36
Reappraisal of known malaria resistance loci in a large multicenter study. 62 57
25261933 2014
37
Patterns of nucleotide and haplotype diversity at ICAM-1 across global human populations with varying levels of malaria exposure. 62 5
23609612 2013
38
Severe malaria is associated with parasite binding to endothelial protein C receptor. 62 57
23739325 2013
39
Glucose-6-phosphate dehydrogenase deficient variants are associated with reduced susceptibility to malaria in the Brazilian Amazon. 62 5
23479361 2013
40
Cytoadherence in paediatric malaria: ABO blood group, CD36, and ICAM1 expression and severe Plasmodium falciparum infection. 62 57
22909232 2012
41
Genome-wide association study indicates two novel resistance loci for severe malaria. 62 57
22895189 2012
42
Hemoglobins S and C interfere with actin remodeling in Plasmodium falciparum-infected erythrocytes. 62 5
22075726 2011
43
Plasmodium falciparum-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endothelium. 62 57
19713460 2009
44
Interaction of malaria with a common form of severe thalassemia in an Asian population. 62 5
19841268 2009
45
A variant in the gene FUT9 is associated with susceptibility to placental malaria infection. 62 57
19460885 2009
46
Association of the GNAS locus with severe malaria. 62 57
18951142 2008
47
Haemoglobin S and haemoglobin C: 'quick but costly' versus 'slow but gratis' genetic adaptations to Plasmodium falciparum malaria. 62 5
18048408 2008
48
Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. 62 57
17959777 2007
49
Combining evidence of natural selection with association analysis increases power to detect malaria-resistance variants. 62 57
17668374 2007
50
Linkage of mild malaria to the major histocompatibility complex in families living in Burkina Faso. 62 57
12566384 2003

Variations for Malaria

ClinVar genetic disease variations for Malaria:

5 (show top 50) (show all 51)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TIRAP NM_001318777.2(TIRAP):c.539C>T (p.Ser180Leu) SNV Protective
4467 rs8177374 GRCh37: 11:126162843-126162843
GRCh38: 11:126292948-126292948
2 FCGR2B NM_001394477.1(FCGR2B):c.695T>C (p.Ile232Thr) SNV Protective
5467 rs1050501 GRCh37: 1:161643798-161643798
GRCh38: 1:161674008-161674008
3 NOS2, LOC111365141 NG_011470.1:g.3828C>T SNV Protective
14013 rs9282799 GRCh37: 17:26128728-26128728
GRCh38: 17:27801702-27801702
4 NOS2 NG_011470.1:g.4047G>C SNV Protective
14014 GRCh37:
GRCh38:
5 CR1 NM_000651.6(CR1):c.4973A>G (p.His1658Arg) SNV Protective
17066 rs2274567 GRCh37: 1:207753621-207753621
GRCh38: 1:207580276-207580276
6 LOC106099062, HBB, LOC107133510 NM_000518.4(HBB):c.19G>A (p.Glu7Lys) SNV Protective
Pathogenic
15126 rs33930165 GRCh37: 11:5248233-5248233
GRCh38: 11:5227003-5227003
7 LOC106099062, HBB, LOC107133510 NM_000518.5(HBB):c.79G>A (p.Glu27Lys) SNV Protective
Pathogenic
15161 rs33950507 GRCh37: 11:5248173-5248173
GRCh38: 11:5226943-5226943
8 LOC106099062, HBB, LOC107133510 NM_000518.5(HBB):c.20A>T (p.Glu7Val) SNV Protective
Pathogenic
Pathogenic
15333 rs334 GRCh37: 11:5248232-5248232
GRCh38: 11:5227002-5227002
9 GYPC NM_002101.4(GYPC):c.107_190del DEL Protective
17725 GRCh37: 2:127451437-127451520
GRCh38: 2:126693861-126693944
10 G6PD NM_000402.4(G6PD):c.653C>T (p.Ser218Phe) SNV Pathogenic
Pathogenic
100057 rs5030868 GRCh37: X:153762634-153762634
GRCh38: X:154534419-154534419
11 G6PD NM_000402.4(G6PD):c.466A>G (p.Asn156Asp) SNV Pathogenic
100055 rs1050829 GRCh37: X:153763492-153763492
GRCh38: X:154535277-154535277
12 G6PD NM_001360016.2(G6PD):c.1315C>T (p.Arg439Cys) SNV Pathogenic
1206418 GRCh37: X:153760650-153760650
GRCh38: X:154532435-154532435
13 G6PD NM_000402.4(G6PD):c.577G>A (p.Gly193Ser) SNV Pathogenic
10367 rs137852314 GRCh37: X:153762710-153762710
GRCh38: X:154534495-154534495
14 SLC4A1 NM_000342.4(SLC4A1):c.1765C>T (p.Arg589Cys) SNV Pathogenic
17764 rs121912745 GRCh37: 17:42333076-42333076
GRCh38: 17:44255708-44255708
15 SLC4A1 NM_000342.4(SLC4A1):c.1199_1225del (p.Ala400_Ala408del) DEL Pathogenic
17753 rs769664228 GRCh37: 17:42335411-42335437
GRCh38: 17:44258043-44258069
16 G6PD NM_000402.4(G6PD):c.1478G>A (p.Arg493His) SNV Pathogenic
100059 rs72554664 GRCh37: X:153760472-153760472
GRCh38: X:154532257-154532257
17 G6PD NM_000402.4(G6PD):c.1093G>A (p.Ala365Thr) SNV Pathogenic
10363 rs5030869 GRCh37: X:153761205-153761205
GRCh38: X:154532990-154532990
18 G6PD NM_000402.4(G6PD):c.961G>A (p.Val321Met) SNV Pathogenic
10386 rs137852327 GRCh37: X:153761337-153761337
GRCh38: X:154533122-154533122
19 G6PD NM_000402.4(G6PD):c.934G>C (p.Asp312His) SNV Pathogenic
10372 rs137852318 GRCh37: X:153761811-153761811
GRCh38: X:154533596-154533596
20 LOC110006319, HBB, LOC107133510 NM_000518.5(HBB):c.316-106C>G SNV Pathogenic
15457 rs34690599 GRCh37: 11:5247062-5247062
GRCh38: 11:5225832-5225832
21 LOC106099062, LOC110006319, HBB, LOC107133510 NM_000518.5(HBB):c.315+1G>A SNV Pathogenic
15438 rs33945777 GRCh37: 11:5247806-5247806
GRCh38: 11:5226576-5226576
22 LOC106099062, HBB, LOC107133510 NM_000518.5(HBB):c.118C>T (p.Gln40Ter) SNV Pathogenic
15402 rs11549407 GRCh37: 11:5248004-5248004
GRCh38: 11:5226774-5226774
23 LOC106099062, HBB, LOC107133510 NM_000518.5(HBB):c.93-21G>A SNV Pathogenic
15454 rs35004220 GRCh37: 11:5248050-5248050
GRCh38: 11:5226820-5226820
24 LOC106099062, HBB, LOC107133510 NM_000518.5(HBB):c.92+6T>C SNV Pathogenic
15450 rs35724775 GRCh37: 11:5248154-5248154
GRCh38: 11:5226924-5226924
25 LOC106099062, HBB, LOC107133510 NM_000518.5(HBB):c.92+5G>C SNV Pathogenic
15447 rs33915217 GRCh37: 11:5248155-5248155
GRCh38: 11:5226925-5226925
26 LOC106099062, HBB, LOC107133510 NM_000518.5(HBB):c.92+1G>A SNV Pathogenic
15436 rs33971440 GRCh37: 11:5248159-5248159
GRCh38: 11:5226929-5226929
27 LOC106099062, HBB, LOC107133510 NM_000518.5(HBB):c.52A>T (p.Lys18Ter) SNV Pathogenic
15401 rs33986703 GRCh37: 11:5248200-5248200
GRCh38: 11:5226970-5226970
28 HBB, LOC106099062, LOC107133510 NM_000518.5(HBB):c.-79A>G SNV Pathogenic
15469 rs34598529 GRCh37: 11:5248330-5248330
GRCh38: 11:5227100-5227100
29 HBB, LOC106099062, LOC107133510 NM_000518.4(HBB):c.-137C>A SNV Pathogenic
36285 rs33941377 GRCh37: 11:5248388-5248388
GRCh38: 11:5227158-5227158
30 LOC110006319, HBB, LOC107133510 NM_000518.4(HBB):c.364G>A (p.Glu122Lys) SNV Pathogenic
15292 rs33946267 GRCh37: 11:5246908-5246908
GRCh38: 11:5225678-5225678
31 LOC106099062, HBB, LOC107133510 NM_000518.5(HBB):c.17_18del (p.Pro6fs) DEL Pathogenic
15422 rs34889882 GRCh37: 11:5248234-5248235
GRCh38: 11:5227004-5227005
32 TNF NM_000594.3(TNF):c.-488G>A SNV Risk Factor
225964 rs1800629 GRCh37: 6:31543031-31543031
GRCh38: 6:31575254-31575254
33 SLC4A1 NM_000342.4(SLC4A1):c.2573C>A (p.Ala858Asp) SNV Likely Pathogenic
17771 rs121912751 GRCh37: 17:42328609-42328609
GRCh38: 17:44251241-44251241
34 CISH, MAPKAPK3 NM_001243926.2(MAPKAPK3):c.-436A>T SNV Risk Factor
7091 rs414171 GRCh37: 3:50649499-50649499
GRCh38: 3:50612068-50612068
35 TNF NG_007462.1:g.4614G>A SNV Risk Factor
12387 GRCh37: 6:31542963-31542963
GRCh38: 6:31575186-31575186
36 CD36 NM_001001548.3(CD36):c.975T>G (p.Tyr325Ter) SNV Risk Factor
13536 rs3211938 GRCh37: 7:80300449-80300449
GRCh38: 7:80671133-80671133
37 CD36 CD36, G1439C, 1-BP DEL, 1444A DEL Risk Factor
13537 GRCh37:
GRCh38:
38 ICAM1 NM_000201.3(ICAM1):c.167A>T (p.Lys56Met) SNV Risk Factor
14661 rs5491 GRCh37: 19:10385540-10385540
GRCh38: 19:10274864-10274864
39 CD36 NM_001001548.3(CD36):c.429+2T>C SNV Likely Pathogenic
417962 rs3211893 GRCh37: 7:80290528-80290528
GRCh38: 7:80661212-80661212
40 HBB, LOC106099062, LOC107133510 NM_000518.5(HBB):c.-138C>A SNV Likely Pathogenic
393701 rs33944208 GRCh37: 11:5248389-5248389
GRCh38: 11:5227159-5227159
41 FCGR2A NM_001136219.3(FCGR2A):c.500A>G (p.His167Arg) SNV Risk Factor
14823 rs1801274 GRCh37: 1:161479745-161479745
GRCh38: 1:161509955-161509955
42 CD36 NM_001001548.3(CD36):c.1254+1G>A SNV Likely Pathogenic
417926 rs148051111 GRCh37: 7:80302726-80302726
GRCh38: 7:80673410-80673410
43 CD36 NM_001001548.3(CD36):c.784dup (p.Gln262fs) DUP Likely Pathogenic
587500 rs766920034 GRCh37: 7:80299302-80299303
GRCh38: 7:80669986-80669987
44 LOC106099062, HBB, LOC107133510 NM_000518.4(HBB):c.208G>A (p.Gly70Ser) SNV Likely Pathogenic
15138 rs33947415 GRCh37: 11:5247914-5247914
GRCh38: 11:5226684-5226684
45 ICAM1 NM_000201.3(ICAM1):c.1432C>T (p.Arg478Trp) SNV Uncertain Significance
828004 rs5030400 GRCh37: 19:10395796-10395796
GRCh38: 19:10285120-10285120
46 FCGR2A NM_001136219.3(FCGR2A):c.780+1G>A SNV Uncertain Significance
1675086 GRCh37: 1:161483723-161483723
GRCh38: 1:161513933-161513933
47 ICAM1 NM_000201.3(ICAM1):c.1212G>A (p.Pro404=) SNV Uncertain Significance
1675090 GRCh37: 19:10395490-10395490
GRCh38: 19:10284814-10284814
48 FCGR2A NM_001136219.3(FCGR2A):c.497C>T (p.Ser166Phe) SNV Uncertain Significance
1675085 GRCh37: 1:161479742-161479742
GRCh38: 1:161509952-161509952
49 ICAM1 NM_000201.3(ICAM1):c.1546C>T (p.Gln516Ter) SNV Uncertain Significance
1675089 GRCh37: 19:10395910-10395910
GRCh38: 19:10285234-10285234
50 NOS2 NM_000625.4(NOS2):c.1172dup (p.Leu392fs) DUP Uncertain Significance
916529 rs1908748329 GRCh37: 17:26105914-26105915
GRCh38: 17:27778888-27778889

Copy number variations for Malaria from CNVD:

6 (show all 17)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 16026 1 12212699 12494685 Indels VPS13D Malaria
2 31007 1 247110827 247119907 Amplification ZNF692 Malaria
3 41121 4 135333667 135338574 Indels DUX4 Malaria
4 61463 12 1 132349534 Indels Malaria
5 64882 12 132073128 132099226 Indels ZNF26 Malaria
6 143470 2 237000000 242951149 Indels Malaria
7 177623 3 59710075 61212173 Indels FHIT Malaria
8 192407 5 112071116 112209835 Indels APC Malaria
9 203647 6 1 170899992 Indels Malaria
10 217046 7 1 158821424 Indels Malaria
11 227212 7 65675806 65694798 Indels Malaria
12 166350 3 10158318 10168746 Indels VHL Malaria
13 82377 14 105461656 105464413 Indels FAM30A Malaria
14 34945 1 5845456 5975118 Indels NPHP4 Malaria
15 243826 8 8897723 8928259 Indels ERI1 Malaria
16 230732 8 1 146274826 Indels Malaria
17 191457 5 1 180857866 Indels Malaria

Expression for Malaria

LifeMap Discovery
Genes differentially expressed in tissues of Malaria patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 MMP9 matrix metallopeptidase 9 Blood + 3.31 0.000
2 C1QB complement C1q B chain Blood + 3.10 0.000
Search GEO for disease gene expression data for Malaria.

Pathways for Malaria

GO Terms for Malaria

Cellular components related to Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005887 9.8 TNF SLC4A1 ICAM1 GYPC GYPB GYPA
2 plasma membrane GO:0005886 9.8 TNF SLC4A1 ICAM1 GYPC GYPB GYPA
3 cortical cytoskeleton GO:0030863 9.43 SLC4A1 NOS2 GYPC

Biological processes related to Malaria according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of interleukin-8 production GO:0032757 9.97 TNF TIRAP NOS2
2 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 CD36 HBB TNF
3 cellular response to lipoteichoic acid GO:0071223 9.78 TIRAP CD36
4 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.76 TNF TIRAP
5 positive regulation of interleukin-6 production GO:0032755 9.76 TNF TIRAP NOS2 CD36
6 negative regulation of immunoglobulin production GO:0002638 9.73 FCGR2B CR1
7 response to bacterium GO:0009617 9.73 TNF NOS2 FCGR2B CD36
8 cellular response to molecule of bacterial origin GO:0071219 9.58 TNF FCGR2B
9 cellular response to bacterial lipopeptide GO:0071221 9.54 TIRAP CD36
10 positive regulation of blood microparticle formation GO:2000334 9.26 TNF CD36
11 cellular response to amyloid-beta GO:1904646 9.23 TNF ICAM1 FCGR2B CD36

Molecular functions related to Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 IgG binding GO:0019864 9.26 FCGR2A FCGR2B
2 hemoglobin binding GO:0030492 8.92 SLC4A1 HBB

Sources for Malaria

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....